1. Describe the process for selecting candidates and how the program will place special emphasis on recruiting qualified women and minorities. The candidate selection process has been in place since the initiation of the program in 1997. Our mechanism for selection of candidates based on merit with consideration of diversity of race, gender, and age among the applicant pool. The Program is administered by the SPORE Director, Dr. Scott E. Kern. The emphasis is on recruitment of young or established investigators from the talented pool throughout the Johns Hopkins Medical Institutions to direct their research career focus upon translational progress in colorectal and pancreatic cancer. The positions are advertised in official Johns Hopkins University and Hospital publications and in memoranda to department and division heads, and informal networking among the faculty throughout the institutions is also emphasized. The advertisements consist of the following: A. A description of the position (career development of new or established investigators that wish to redirect their efforts specifically in the area of translational research into colorectal and/or pancreatic cancer B. A statement that two positions are available, each offer $40,000/year of salary support C. A statement that candidates will be selected by the Career Development Committee with approval by the SPORE Steering Committee. D. A list of selection criteria and of the Committee members (see below). E. Applications are due by a set date each February, for starting dates of the following July 1. This distribution of dates has encouraged departments to cooperation with the SPORE to plan ahead, in order to protect the research time of the awardee and maximize their translational career. F. Inquiries should be made to Scott E. Kern, MD, Assoc. Professor of Oncology and Pathology, 451 Cancer Research Bldg., The Johns Hopkins Univ. School of Medicine, 1650 Orleans Street, Baltimore, MD 21231; Phone 410-614-3314, Fax 443-287-4653, email sk@ihmi.edu G. The Johns Hopkins University is an Equal Opportunity, Affirmative Action Employer. Minorities, women, Vietnam-era veterans, disabled veterans, and individuals with disabilities are encouraged to apply.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-15
Application #
7686211
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
15
Fiscal Year
2008
Total Cost
$119,357
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications